AIDIA

AIDIA is a South Korean clinical-stage biotechnology company specializing in the discovery and development of novel therapeutics for central nervous system (CNS) disorders, with a primary focus on Alzheimer's disease. The company leverages a proprietary AI-driven drug discovery platform to identify and optimize small molecule candidates that target neuroinflammation and neurodegeneration. Its lead program, AD-101, is a multi-target small molecule currently in Phase 2 clinical trials for the treatment of Alzheimer's disease, demonstrating the company's ability to transition from computational discovery to clinical validation. AIDIA's pipeline also includes early-stage programs for Parkinson's disease and other rare neurological conditions. The company aims to overcome the traditional challenges of CNS drug development by integrating advanced data analytics with deep biological expertise.